SLC5A2 and Obesity: Based on the recent warnings from the FDA, SEGO, EMA and AEMPS and the drastic growing popularity of therapy with SGLT2 inhibitors, especially rising quickly worldwide along with the increased needs of diabetic patients with heart disease and obesity, it is important to consider the possible and fatal adverse effects [6,12].